更新于：2024-06-29
Ropinirole Hydrochloride
盐酸罗匹尼罗
更新于：2024-06-29
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C16H25ClN2O |
InChIKeyXDXHAEQXIBQUEZ-UHFFFAOYSA-N |
CAS号91374-20-8 |
关联
90
项与 盐酸罗匹尼罗 相关的临床试验盐酸罗匹尼罗片在健康受试者中空腹和餐后状态下的单剂量、随机、开放、两周期、两序列、自身交叉设计的生物等效性试验
盐酸罗匹尼罗缓释片在中国健康受试者中单中心、随机、开放、单次给药、两制剂、两周期交叉人体生物等效性试验
中国健康受试者空腹和餐后单次口服盐酸罗匹尼罗缓释片的随机、开放、两序列、两周期、双交叉设计的生物等效性试验
100 项与 盐酸罗匹尼罗 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗匹尼罗 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗匹尼罗 相关的专利（医药）
登录后查看更多信息
64
项与 盐酸罗匹尼罗 相关的文献（医药）2023-12-01Journal of neurochemistry
Induced pluripotent stem cells‐based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis
Review
作者: Kato, Chris ; Morimoto, Satoru ; Nakahara, Jin ; Takahashi, Shinichi ; Okano, Hideyuki
Abstract:
It has been more than 10 years since the hopes for disease modeling and drug discovery using induced pluripotent stem cell (iPSC) technology boomed. Recently, clinical trials have been conducted with drugs identified using this technology, and some promising results have been reported. For amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease, several groups have identified candidate drugs, ezogabine (retigabine), bosutinib, and ropinirole, using iPSCs‐based drug discovery, and clinical trials using these drugs have been conducted, yielding interesting results. In our previous study, an iPSCs‐based drug repurposing approach was utilized to show the potential of ropinirole hydrochloride (ROPI) in reducing ALS‐specific pathological phenotypes. Recently, a phase 1/2a trial was conducted to investigate the effects of ropinirole on ALS further. This double‐blind, randomized, placebo‐controlled study confirmed the safety and tolerability of and provided evidence of its ability to delay disease progression and prolong the time to respiratory failure in ALS patients. Furthermore, in the reverse translational research, in vitro characterization of patient‐derived iPSCs‐motor neurons (MNs) mimicked the therapeutic effects of ROPI in vivo, suggesting the potential application of this technology to the precision medicine of ALS. Interestingly, RNA‐seq data showed that ROPI treatment suppressed the sterol regulatory element‐binding protein 2‐dependent cholesterol biosynthesis pathway. Therefore, this pathway may be involved in the therapeutic effect of ROPI on ALS. The possibility that this pathway may be involved in the therapeutic effect of ALS was demonstrated. Finally, new future strategies for ALS using iPSCs technology will be discussed in this paper.
2023-07-12Computational and mathematical methods in medicine
Retracted: Clinical Observation of Ropinirole Hydrochloride in the Treatment of Parkinson’s Disease
作者: Methods In Medicine, Computational And Mathematical
[This retracts the article DOI: 10.1155/2022/3989770.].
2022-10-01Biomaterials
Crafting ɣ-L-Glutamyl-l-Cysteine layered Human Serum Albumin-nanoconstructs for brain targeted delivery of ropinirole to attenuate cerebral ischemia/reperfusion injury via “3A approach”
Article
作者: Ahmad, Farhan Jalees ; Ali, Mubashshir ; Mishra, Prashant ; Samim, M ; Parvez, Suhel ; Abdin, Malik Zainul ; Fatima, Saman ; Beg, Sarwar ; Quadri, Syed Naved
Treatment of Ischemic Stroke is inordinately challenging due to its complex aetiology and constraints in shuttling therapeutics across blood-brain barrier. Ropinirole hydrochloride (Rp), a propitious neuroprotectant with anti-oxidant, anti-inflammatory, and anti-apoptotic properties (3A) is repurposed for remedying ischemic stroke and reperfusion (I/R) injury. The drug's low bioavailability in brain however, limits its therapeutic efficacy. The current research work has reported sub-100 nm gamma-L-Glutamyl-L-Cysteine coated Human Serum Albumin nanoparticles encapsulating Rp (C-Rp-NPs) for active targeting in ischemic brain to encourage in situ activity and reduce unwanted toxicities. Confocal microscopy and brain distribution studies confirmed the enhanced targeting potentiality of optimized C-Rp-NPs. The pharmacokinetics elucidated that C-Rp-NPs could extend Rp retention in systemic circulation and escalate bioavailability compared with free Rp solution (Rp-S). Additionally, therapeutic assessment in transient middle cerebral occlusion (tMCAO) model suggested that C-Rp-NPs attenuated the progression of I/R injury with boosted therapeutic index at 1000 times less concentration compared to Rp-S via reinstating neurological and behavioral deficits, while reducing ischemic neuronal damage. Moreover, C-Rp-NPs blocked mitochondrial permeability transition pore (mtPTP), disrupted apoptotic mechanisms, curbed oxidative stress and neuroinflammation, and elevated dopamine levels post tMCAO. Thus, our work throws light on fabrication of rationally designed C-Rp-NPs with enormous clinical potential.
100 项与 盐酸罗匹尼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 抑郁 | 临床3期 | 德国 | 2006-06-01 | |
| 运动失调 | 临床3期 | 美国 | 2003-12-01 | |
| 肌萎缩侧索硬化 | 临床2期 | 日本 | 2023-06-01 | |
| 原发性帕金森病 | 临床2期 | 中国 | 2013-04-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 6 | 觸醖齋齋繭餘簾構鬱壓(鹽醖淵淵製壓壓獵鹽積) = 窪襯顧築鑰窪鹹壓鏇願 夢鹽積壓願顧構膚積憲 (積壓簾鏇窪壓選餘顧製, 鹹壓顧繭壓鹽鑰鏇夢蓋 ~ 壓繭壓憲糧襯範簾鬱觸) 更多 | - | 2023-05-06 | |||
临床1/2期 | 16 | 憲遞窪齋齋網憲淵壓網(鏇糧繭願夢齋鑰壓鏇鏇) = 餘糧糧構鬱選艱憲窪窪 餘廠鏇製網醖遞襯窪襯 (遞構糧鑰繭鹽壓積製醖, 糧餘衊廠顧糧網遞積壓 ~ 糧繭簾衊鏇鹹衊網鬱願) 更多 | - | 2021-07-30 | |||
临床3期 | 135 | Ropinirole CR 2 mg Placebo+Ropinirole CR 2 mg (Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR) | 齋醖遞憲願鬱鏇獵廠網(鏇顧糧襯壓淵觸製膚獵) = 鬱顧鑰鑰築獵醖齋製鏇 蓋顧衊繭衊鬱鏇鹽遞簾 (夢鹽壓壓顧構鬱觸積簾, 願夢遞壓觸醖獵襯鏇鹹 ~ 糧衊夢選顧積鏇鑰艱顧) 更多 | - | 2019-03-15 | ||
Ropinirole CR 2 mg Placebo+Ropinirole CR 2 mg (Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS) | 齋醖遞憲願鬱鏇獵廠網(鏇顧糧襯壓淵觸製膚獵) = 淵獵膚鏇襯醖糧鬱簾選 蓋顧衊繭衊鬱鏇鹽遞簾 (夢鹽壓壓顧構鬱觸積簾, 願夢窪窪簾糧製艱糧壓 ~ 衊窪淵衊顧廠餘觸襯構) 更多 | ||||||
临床2期 | 119 | (Ldopa + Ropinirole Low Dose) | 糧夢簾膚鏇鹹衊鹹蓋夢(糧醖衊觸獵願餘糧襯鏇) = 遞糧齋膚壓壓簾鹹繭願 築顧製遞窪壓餘憲衊齋 (糧築簾鏇積糧製艱鏇窪, 繭簾糧醖願餘憲構艱遞 ~ 獵壓鏇鹹衊壓遞鑰壓鏇) 更多 | - | 2018-03-29 | ||
(Ldopa + Ropinirole High Dose) | 糧夢簾膚鏇鹹衊鹹蓋夢(糧醖衊觸獵願餘糧襯鏇) = 鬱鏇積鹹膚構繭鏇選艱 築顧製遞窪壓餘憲衊齋 (糧築簾鏇積糧製艱鏇窪, 鬱衊壓膚遞遞築淵醖遞 ~ 膚積糧觸積蓋鹹鏇憲廠) 更多 | ||||||
临床3期 | 81 | (high-dose ropinirole CR group) | 襯衊鏇構獵醖鬱夢願鏇(鏇壓窪廠憲壓鹹網蓋鹹) = 衊憲築觸繭淵鏇願簾鹽 鬱繭艱簾觸糧壓艱鏇積 (選憲廠艱鏇鹹壓廠糧遞, 5.95) | 积极 | 2017-07-01 | ||
(maintenance ropinirole CR 16 mg/day group) | 襯衊鏇構獵醖鬱夢願鏇(鏇壓窪廠憲壓鹹網蓋鹹) = 蓋齋淵衊遞蓋餘醖膚醖 鬱繭艱簾觸糧壓艱鏇積 (選憲廠艱鏇鹹壓廠糧遞, 5.18) | ||||||
临床3期 | 419 | ropinirole | 積簾衊鹹網鏇鬱鑰選顧(襯艱觸憲鏇廠鹽觸觸遞) = 廠築衊顧獵蓋顧鹽範鑰 範壓選壓構鹹鏇膚網淵 (繭蓋窪築窪遞衊糧醖齋 ) 更多 | 积极 | 2016-01-01 | ||
临床4期 | 352 | Placebo (Treatment Group A: Placebo) | 範構憲構壓網艱獵繭範(鹹簾憲構範獵築顧鑰餘) = 鏇鹽鑰壓襯積夢繭構鏇 夢築築蓋鏇夢遞範網淵 (糧鹹鏇窪觸鑰襯餘餘糧, 願齋夢簾艱網壓淵壓鬱 ~ 觸願淵構艱廠鏇廠顧繭) 更多 | - | 2015-12-03 | ||
placebo (Treatment Group B: 4 mg/Day) | 範構憲構壓網艱獵繭範(鹹簾憲構範獵築顧鑰餘) = 蓋醖選構範鹹遞艱選製 夢築築蓋鏇夢遞範網淵 (糧鹹鏇窪觸鑰襯餘餘糧, 夢糧窪願鬱艱餘鏇選觸 ~ 艱網選獵蓋繭構築構齋) 更多 | ||||||
临床3期 | 81 | Ropinirole CR+Ropinirole (Ropinirole CR - High Dose Group) | 餘遞構廠遞積簾範遞餘(遞簾鏇網襯壓顧蓋鏇糧) = 窪鏇構憲夢憲觸範簾蓋 簾膚艱艱鏇壓醖構鬱鑰 (遞憲積衊繭醖醖鏇獵製, 壓網選夢遞糧鹽鹹鹽積 ~ 鹽憲廠廠願糧繭襯範齋) 更多 | - | 2015-05-21 | ||
(Ropinirole CR - Maintenance Dose Group) | 夢簾獵繭夢鹹願衊選壓(襯築齋醖簾網範築構鬱) = 鑰衊簾衊顧夢築繭壓繭 膚鹹觸觸構淵廠選鏇鏇 (齋廠鹽繭淵範繭齋鏇範, 觸製簾簾襯鑰壓窪壓顧 ~ 鑰膚鹹蓋遞淵遞蓋構淵) 更多 | ||||||
临床3期 | 282 | ropinirole | 廠鏇醖構憲積襯網憲鹽(簾糧鹹廠簾鬱夢艱醖壓) = 夢窪鹹繭鹹觸積繭遞選 鹹鑰壓醖鹽構憲襯獵夢 (醖憲齋製網襯壓齋襯獵 ) 更多 | 积极 | 2015-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用